Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Heron Therapeutics, Inc. (NASDAQ: HRTX).

Full DD Report for HRTX

You must become a subscriber to view this report.

Recent News from (NASDAQ: HRTX)

Heron Therapeutics misses by $0.04, beats on revenue
Heron Therapeutics (NASDAQ: HRTX ): Q3 GAAP EPS of -$0.49 misses by $0.04 . More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:24
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Corporate Progress
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial ...
Source: PR Newswire
Date: November, 07 2018 16:05
Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the...
Source: PR Newswire
Date: October, 31 2018 16:01
Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Heron's Way Ahead: Is There Further Upside?
Heron Therapeutics ( HRTX ) is an emerging biopharma with two drugs - SUSTOL and CINVANTI - both approved for preventing CINV or Chemotherapy-Induced Nausea and Vomiting. The company has had an excellent year, going up almost 3x on the basis of these approvals. However, what we like about HRTX...
Source: SeekingAlpha
Date: August, 28 2018 14:06
New Research Coverage Highlights East West, Heron Therapeutics, Invacare, CNO Financial Group, Fortinet, and Realogy - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of East West Bancorp, Inc. (NASDAQ:EWBC), Heron Therapeutics, Inc. (NASDAQ:H...
Source: GlobeNewswire
Date: August, 13 2018 08:00


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HRTX.

About Heron Therapeutics, Inc. (NASDAQ: HRTX)

Logo for Heron Therapeutics, Inc. (NASDAQ: HRTX)

Not available


Contact Information



Current Management

  • Barry D. Quart / CEO
  • Robert Rosen / President
  • Stephen R. Davis / COO, EVP
  • Brian G. Drazba / CFO
  • Mark S. Gelder, M.D. / Chief Med. Officer
  • Edie DeVine / IR

Current Share Structure

  • Market Cap: $2,075,213,094 - 05/16/2018
  • Issue and Outstanding: 71,951,009 - 04/25/2018


Daily Technical Chart for (NASDAQ: HRTX)

Daily Technical Chart for (NASDAQ: HRTX)

Stay tuned for daily updates and more on (NASDAQ: HRTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: HRTX)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HRTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HRTX and does not buy, sell, or trade any shares of HRTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: